BR0014895A - Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais - Google Patents

Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais

Info

Publication number
BR0014895A
BR0014895A BR0014895-4A BR0014895A BR0014895A BR 0014895 A BR0014895 A BR 0014895A BR 0014895 A BR0014895 A BR 0014895A BR 0014895 A BR0014895 A BR 0014895A
Authority
BR
Brazil
Prior art keywords
sodium
polyethylene glycol
potassium salt
atpase inhibitor
gastrointestinal diseases
Prior art date
Application number
BR0014895-4A
Other languages
English (en)
Inventor
Mikael Bruells
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0014895A publication Critical patent/BR0014895A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMULAçãO LìQUIDA ESTáVEL, PROCESSO PARA A PREPARAçãO DA MESMA, USO DA MESMA, USO DE POLIETILENO GLICOL E SAL DE SóDIO OU POTáSSIO DE UM INIBIDOR H^ +^, K^ +^-ATPASE, E, MéTODO PARA TRATAR DOENçAS GASTROINTESTINAIS". A presente invenção diz respeito a formulações líquidas estáveis que compreendem uma solução de polietileno glicol anidra ou quase anidra de sal de sódio ou potássio de um inibidor H^ +^, K^ +^-ATPase de fórmula (1) ou um sal de sódio ou potássio de um enanciómero único deste. Alternativamente, o sal de sódio ou potássio do inibidor H^ +^, K^ +^-ATPase pode ser formado in situ na solução de glicol de polietileno pela adição de hidróxido de sódio ou potássio ao mesmo tempo e o composto ativo. A invenção é também dirigida à preparação da formulação reivindicada, uso das formulações líquidas estáveis na medicina e no tratamento de doenças gastrointestinais.
BR0014895-4A 1999-10-22 2000-10-13 Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais BR0014895A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles
PCT/SE2000/001992 WO2001028558A1 (en) 1999-10-22 2000-10-13 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
BR0014895A true BR0014895A (pt) 2002-06-18

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014895-4A BR0014895A (pt) 1999-10-22 2000-10-13 Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais

Country Status (36)

Country Link
US (1) US6730685B1 (pt)
EP (1) EP1274427B1 (pt)
JP (1) JP2003512327A (pt)
KR (1) KR100785603B1 (pt)
CN (1) CN1213751C (pt)
AR (1) AR029005A1 (pt)
AT (1) ATE304851T1 (pt)
AU (1) AU782866B2 (pt)
BG (1) BG65580B1 (pt)
BR (1) BR0014895A (pt)
CA (1) CA2425199C (pt)
CO (1) CO5261533A1 (pt)
CY (1) CY1106055T1 (pt)
CZ (1) CZ20021375A3 (pt)
DE (1) DE60022789T2 (pt)
DK (1) DK1274427T3 (pt)
EE (1) EE05175B1 (pt)
ES (1) ES2246903T3 (pt)
HK (1) HK1051142A1 (pt)
HU (1) HUP0203121A3 (pt)
IL (2) IL149107A0 (pt)
IS (1) IS2196B (pt)
MX (1) MXPA02003900A (pt)
MY (1) MY131971A (pt)
NO (1) NO329545B1 (pt)
NZ (1) NZ518155A (pt)
PL (1) PL199868B1 (pt)
RU (1) RU2286782C2 (pt)
SE (1) SE9903831D0 (pt)
SI (1) SI1274427T1 (pt)
SK (1) SK286266B6 (pt)
TR (1) TR200201103T2 (pt)
TW (1) TWI236372B (pt)
UA (1) UA74347C2 (pt)
WO (1) WO2001028558A1 (pt)
ZA (1) ZA200202905B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417311C (en) * 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
US7396841B2 (en) * 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US7507746B2 (en) * 2003-02-24 2009-03-24 Mitsubishi Pharma Corporation Enantiomer of tenatoprazole and the use thereof in therapy
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
BRPI0711048A2 (pt) * 2006-05-09 2011-08-23 Astrazeneca Ab formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
WO2016077185A1 (en) 2014-11-13 2016-05-19 3M Innovative Properties Company Kit comprising atp-diphosphohydrolase for detecting bacterial atp in a sample
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
ES2093445T3 (es) 1992-07-28 1996-12-16 Astra Ab Inyeccion y estuche de inyeccion que contiene omeprazol y sus analogos.
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
NZ518155A (en) 2004-07-30
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
IL149107A0 (en) 2002-11-10
US6730685B1 (en) 2004-05-04
SI1274427T1 (sl) 2006-02-28
NO20021860L (no) 2002-05-21
EE05175B1 (et) 2009-06-15
CA2425199C (en) 2010-12-07
NO329545B1 (no) 2010-11-08
KR100785603B1 (ko) 2007-12-14
IS6347A (is) 2002-04-17
ATE304851T1 (de) 2005-10-15
HUP0203121A2 (hu) 2003-01-28
AU1182301A (en) 2001-04-30
KR20020059637A (ko) 2002-07-13
SE9903831D0 (sv) 1999-10-22
WO2001028558A1 (en) 2001-04-26
EP1274427A1 (en) 2003-01-15
TR200201103T2 (tr) 2002-08-21
PL199868B1 (pl) 2008-11-28
CN1382048A (zh) 2002-11-27
CN1213751C (zh) 2005-08-10
ZA200202905B (en) 2003-07-14
AR029005A1 (es) 2003-06-04
SK5392002A3 (en) 2002-10-08
CO5261533A1 (es) 2003-03-31
CA2425199A1 (en) 2001-04-26
BG65580B1 (bg) 2009-01-30
IL149107A (en) 2008-04-13
RU2286782C2 (ru) 2006-11-10
EP1274427B1 (en) 2005-09-21
NO20021860D0 (no) 2002-04-19
HK1051142A1 (en) 2003-07-25
HUP0203121A3 (en) 2004-01-28
DK1274427T3 (da) 2005-12-27
EE200200204A (et) 2003-04-15
JP2003512327A (ja) 2003-04-02
SK286266B6 (sk) 2008-06-06
BG106602A (en) 2002-12-29
MXPA02003900A (es) 2002-09-30
TWI236372B (en) 2005-07-21
IS2196B (is) 2007-01-15
CY1106055T1 (el) 2011-04-06
MY131971A (en) 2007-09-28
ES2246903T3 (es) 2006-03-01
CZ20021375A3 (cs) 2002-09-11
AU782866B2 (en) 2005-09-01
UA74347C2 (uk) 2005-12-15
PL354926A1 (en) 2004-03-22

Similar Documents

Publication Publication Date Title
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
PA8452201A1 (es) Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos.
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
NO2005024I2 (no) Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samtfarmasoytisk blanding, produkt, utstyrsett og fre mgangsmaate for in vitro-diagnostisering
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
MD960307A (ro) Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii
DE69616749T2 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
DK360187D0 (da) Diphenylpropylaminderivater, deres fremstilling og anvendelse
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
FI102964B1 (fi) Terapeuttisia yhdisteitä
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
RU2002121636A (ru) Производные индола в качестве антагонистов рецепторов мср-1
GT199900171A (es) Concentrado oral de sertralina.
AR008245A1 (es) Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
NO923198L (no) Terapeutiske midler
ES477630A1 (es) Procedimiento para la obtencion de preparados farmaceuticos desintoxicados de agentes alcohilantes citostaticamente efi-caces.
RU2085194C1 (ru) Средство для местного применения

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/44, A61K 47/30

Ipc: A61K 9/08 (2010.01), A61K 31/44 (2010.01), A61K 47

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.